01:19 PM EDT, 06/28/2024 (MT Newswires) -- Bluejay Diagnostics ( BJDX ) said it closed Friday an underwritten public offering of under 5.4 million common or prefunded units, with expected gross proceeds of roughly $8.8 million.

Net proceeds will be used to repay $2.3 million in debt, finance clinical studies and other activities related to seeking US Food and Drugs Administration approval, and for general working capital, the company said.

Bluejay Diagnostics' ( BJDX ) shares fell 6.8% in recent trading Friday.

Price: 0.70, Change: -0.05, Percent Change: -6.80